March 6, 2019 07:00 AM ESTUpdated March 6, 09:08 PM
Financing

Gene edit­ing up­start backed by Broad star Feng Zhang nabs $135M, blue­print­ing a plat­form biotech for the long haul

John Carroll

Editor & Founder

Im­age: John Evans. BEAM

Last May, when Beam Ther­a­peu­tics had its com­ing out par­ty, com­plete with $87 mil­lion in in­vest­ment back­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

Neu­ro­gene's stock falls in post-mar­ket trad­ing af­ter ear­ly da­ta in Rett syn­drome

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times